SUSMED

SUSMED

Financials

Estimates*

Edit
Revenues, earnings & profits over time
JPY2020202120222023202420252026
Revenues34.9m115m317m531m346m600m1.3b
% growth-231 %174 %67 %(35 %)73 %117 %
EBITDA(153m)(329m)(211m)(37.5m)(454m)(385m)(80.0m)
% EBITDA margin(438 %)(285 %)(67 %)(7 %)(131 %)(64 %)(6 %)
Profit(96.9m)(278m)(233m)(50.7m)(457m)(390m)(85.0m)
% profit margin(278 %)(240 %)(74 %)(10 %)(132 %)(65 %)(7 %)
EV / revenue--30.9x46.2x14.7x9.4x4.5x
EV / EBITDA---46.4x-652.5x-11.2x-14.6x-73.2x
R&D budget86.4m249m226m176m---
R&D % of revenue248 %216 %71 %33 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

JPY10.0m

Early VC

$870k

Seed

$6.5m

Early VC

N/A

Early VC
N/A

N/A

Early VC
N/A

N/A

Early VC
N/A

N/A

IPO
Total Funding$7.5m

Recent News about SUSMED

Edit
More about SUSMEDinfo icon
Edit

Susmed Inc. operates in the healthcare and pharmaceutical sectors, focusing on providing advanced clinical trial solutions. The company leverages cutting-edge technologies such as blockchain and artificial intelligence (AI) to enhance the efficiency and reliability of clinical trials. Their primary clients include pharmaceutical companies, hospitals, academic institutions, and health insurance providers. Susmed's business model revolves around offering a comprehensive platform that integrates clinical development systems, enabling seamless monitoring and data management for clinical trials. The company generates revenue through service fees and subscription models for their platform. By streamlining the clinical trial process, Susmed aims to accelerate the approval of medical equipment and pharmaceuticals, ultimately contributing to improved healthcare outcomes.

Keywords: clinical trials, blockchain, AI, pharmaceuticals, healthcare, data management, hospitals, academic institutions, health insurance, medical equipment.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.